The correlation of ADMA with proinflammatory, liver injury and cancer biomarkers in patients with liver dysfunction.

IF 1.2 Q4 GASTROENTEROLOGY & HEPATOLOGY

Hepatology Forum Pub Date : 2024-03-25 eCollection Date: 2024-01-01 DOI:10.14744/hf.2023.2023.0068

Agnieszka Lembas, Tomasz Mikuła, Mariusz Sapuła, Szymon Barczak, Barbara Badura, Alicja Wiercińska Drapało

{"title":"The correlation of ADMA with proinflammatory, liver injury and cancer biomarkers in patients with liver dysfunction.","authors":"Agnieszka Lembas, Tomasz Mikuła, Mariusz Sapuła, Szymon Barczak, Barbara Badura, Alicja Wiercińska Drapało","doi":"10.14744/hf.2023.2023.0068","DOIUrl":null,"url":null,"abstract":"Background and aim: Asymmetric dimethylarginine (ADMA) is an enzyme involved in vascular tone, blood pressure, and platelet activation. Serum ADMA levels are increased in liver diseases such as liver cirrhosis, hepatitis, and acute liver failure. The aim of our study was to assess the correlation of ADMA with proinflammatory, liver injury, and cancer biomarkers in patients with liver dysfunction of various etiologies.Materials and methods: We analyzed the demographic and clinical data, including serum ADMA concentration and other biochemical markers such as albumin, platelet count, international normalized ratio, bilirubin, and others in patients with hepatitis, compensated and decompensated liver cirrhosis, and hepatocellular carcinoma. The one-way ANOVA, Student's t-test, Mann-Whitney U test, univariate, and multivariate correlations were performed, and a p-value <0.05 was set as significant.Results: In n=83 analyzed patients, we observed a negative correlation of ADMA with albumin concentration (p=0.049). We found a negative correlation between ADMA and platelet count in n=31 patients with compensated liver cirrhosis (p=0.022). We observed no significant correlations of ADMA with proinflammatory and cancer biomarkers in patients with hepatitis, compensated and decompensated liver cirrhosis, and hepatocellular carcinoma.Conclusion: ADMA can potentially be used as a subsidiary marker of disease progression in patients with liver dysfunction. Our research suggests that ADMA cannot be useful in detecting hepatocellular carcinoma (HCC).","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"5 4","pages":"171-177"},"PeriodicalIF":1.2000,"publicationDate":"2024-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440223/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatology Forum","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14744/hf.2023.2023.0068","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and aim: Asymmetric dimethylarginine (ADMA) is an enzyme involved in vascular tone, blood pressure, and platelet activation. Serum ADMA levels are increased in liver diseases such as liver cirrhosis, hepatitis, and acute liver failure. The aim of our study was to assess the correlation of ADMA with proinflammatory, liver injury, and cancer biomarkers in patients with liver dysfunction of various etiologies.

Materials and methods: We analyzed the demographic and clinical data, including serum ADMA concentration and other biochemical markers such as albumin, platelet count, international normalized ratio, bilirubin, and others in patients with hepatitis, compensated and decompensated liver cirrhosis, and hepatocellular carcinoma. The one-way ANOVA, Student's t-test, Mann-Whitney U test, univariate, and multivariate correlations were performed, and a p-value <0.05 was set as significant.

Results: In n=83 analyzed patients, we observed a negative correlation of ADMA with albumin concentration (p=0.049). We found a negative correlation between ADMA and platelet count in n=31 patients with compensated liver cirrhosis (p=0.022). We observed no significant correlations of ADMA with proinflammatory and cancer biomarkers in patients with hepatitis, compensated and decompensated liver cirrhosis, and hepatocellular carcinoma.

Conclusion: ADMA can potentially be used as a subsidiary marker of disease progression in patients with liver dysfunction. Our research suggests that ADMA cannot be useful in detecting hepatocellular carcinoma (HCC).

查看原文本刊更多论文

肝功能异常患者体内 ADMA 与促炎、肝损伤和癌症生物标志物的相关性。

背景和目的：不对称二甲基精氨酸（ADMA）是一种参与血管张力、血压和血小板活化的酶。肝硬化、肝炎和急性肝衰竭等肝病患者的血清 ADMA 水平会升高。我们的研究旨在评估各种病因导致的肝功能异常患者体内 ADMA 与促炎、肝损伤和癌症生物标志物的相关性：我们分析了肝炎、代偿期和失代偿期肝硬化以及肝细胞癌患者的人口统计学和临床数据，包括血清 ADMA 浓度和其他生化指标，如白蛋白、血小板计数、国际标准化比值、胆红素等。进行了单因素方差分析、学生 t 检验、曼-惠特尼 U 检验、单变量和多变量相关性分析，并得出了 P 值结果：在分析的 83 名患者中，我们观察到 ADMA 与白蛋白浓度呈负相关（P=0.049）。在 31 名肝硬化代偿期患者中，我们发现 ADMA 与血小板计数呈负相关（p=0.022）。我们观察到，在肝炎、代偿期和失代偿期肝硬化以及肝细胞癌患者中，ADMA与促炎和癌症生物标志物无明显相关性：ADMA可作为肝功能异常患者疾病进展的辅助标志物。我们的研究表明，ADMA 不能用于检测肝细胞癌（HCC）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hepatology Forum

CiteScore

1.90

自引率

12.50%

发文量